Senores-new-logo-Oct-2023Senores-new-logo-Oct-2023Senores-new-logo-Oct-2023Senores-new-logo-Oct-2023
  • About Us
    • About Senores
    • Milestone
    • Leadership
      • Board of Directors
      • Senior Management
    • Partnership
    • Corporate Film
  • Manufacturing
    • Formulations
    • API
  • Products
    • Formulation – Regulated Market
    • Formulation – Emerging Market
    • API
    • Critical Care – Hospital Line
    • Private Label
  • R&D
  • Investors
    • Announcements
    • Financials
    • Shareholding Pattern
    • Corporate Governance Reports
    • Reports
    • Policies
    • Committees
    • Investor Meet
    • Investor Contacts
    • MOA-AOA
    • Reg. 46 of SEBI (LODR) Regulations
    • Offer Documents
  • Contact

Reports
Annual Reports
    • Annual Report FY 2024-25 (Corrigendum)
    • Annual Report FY 2024-2025
    • Annual Report FY 2023-2024
    • Annual Report FY 2022-2023
    • Annual Report FY 2021-2022
Annual Returns
  • Annual Return in form MGT-7 for F.Y. 2023-2024
  • Annual Return in form MGT-7 for F.Y. 2022-2023
  • Annual Return in form MGT-7 for F.Y. 2021-2022
  • Annual Return in form MGT-7 for F.Y. 2020-2021
Secretarial Compliance Report
  • Annual Secretarial Compliance Report for FY 2024-25 – 28.05.2025
Secretarial Audit Reports
  • Secretarial Audit Report for FY 2024-25

Useful Links

  • About Us
  • Manufacturing
  • Products
  • Partnership
  • R&D
  • Regulatory
  • Adverse Drug Reaction Reporting Form
  • Media
  • Career
  • Contact

Disclaimer

• All the information present on Senores Pharmaceuticals website is not applicable to all the countries across the world. The  purpose  of   this  website is to provide information about Senores Pharmaceuticals' products and services. Any information present on the website shouldn't be misused or construed to spread or promote any of the products in the countries where are disapproved or prohibited.
• Listed  products  in this website will not be supplied to countries in which these could be in conflict with existing valid patents. The buyers should make their independent evaluation of the patent scenario for their respective market as the final responsibility lies exclusively with the buyer.
• Patented products will only be supplied for development, testing, and regulatory submission purposes.

© 2023 Senores Pharmaceuticals | All Rights Reserved.